We are using cookies in order to facilitate your navigation on this website. You can read about how we use cookies and how to manage them here. By continuing to navigate on this website or clicking on the button, you accept our cookie notice and related Privacy Policy.
I accept the use of cookies
Molecular Partners
  • Partnering
  • Careers
  • Contact Us
  • About Us
  • Our DARPin® Platform
  • Our Approach
  • Pipeline
  • Investors
    • Share Information
    • Analyst Coverage
    • News Releases
    • Investor & Scientific Documents
    • General Meetings
    • Governance & Compliance
    • Financial Calendar & Events
    • Investor Contact
    • Register for Email News
  • News
  • Home
  • About Us
  • Our DARPin® Platform
  • Our Approach
  • Pipeline
  • Investors
      « Back
    • Investors
    • Share Information
    • Analyst Coverage
    • News Releases
    • Investor & Scientific Documents
    • General Meetings
    • Governance & Compliance
    • Financial Calendar & Events
    • Investor Contact
    • Register for Email News
  • News
  • Partnering
  • Careers
  • Contact Us

Pipeline

Pipeline

Our DARPin® engine is an unlimited source of novel therapeutic designs. Explore our pipeline:

Candidate / Focus
Research
Preclinical
Phase 1
Phase 2
Phase 3
Rights
Ensovibep (MP0420) / COVID-19
Preclinical
MP0423 / COVID-19
Preclinical
MP0310 / FAP x 4-1BB
Phase 1
MP0317 / FAP x CD-40
Preclinical
CD3 / T-Cell targeting DARPins
Preclinical
Peptide-MHC targeting DARPins
Research
MP0250 / Multiple myeloma / PI combo
Phase 2
MP0274 / HER2+ tumors
Phase 1
Abicipar / Neovascular AMD
Phase 3
Abicipar / DME
Phase 3
  • Cookie Notice
  • Privacy & Disclaimer
  • Contact Us

© 2021 Molecular Partners.